Skip to main content
. 2014 Jun;58(6):3429–3436. doi: 10.1128/AAC.02497-13

FIG 2.

FIG 2

Patient disposition. Footnotes: a, one patient experienced severe bone pain during PR lead-in and discontinued before receiving FDV; b, includes lack of efficacy and lost to follow-up. QD, once daily; PR, pegylated interferon α-2a and ribavirin; mRVR, maintained rapid virologic response (HCV RNA below the lower limit of quantification [LLOQ; <25 IU/ml] at week 4 and undetectable at weeks 8 and 12).